Helix BioPharma Corp. Stock price

Equities

HBP

CA4229101098

Biotechnology & Medical Research

Market Closed - Toronto S.E. 09:30:00 2024-03-18 am EDT 5-day change 1st Jan Change
0.18 CAD -5.26% Intraday chart for Helix BioPharma Corp. -2.70% -14.29%
Sales 2022 - Sales 2023 - Capitalization 42M 56.97M
Net income 2022 -6M -8.14M Net income 2023 -6M -8.14M EV / Sales 2022 -
Net cash position 2022 784K 1.06M Net cash position 2023 808K 1.1M EV / Sales 2023 -
P/E ratio 2022
-4.33 x
P/E ratio 2023
-6.45 x
Employees 9
Yield 2022 *
-
Yield 2023
-
Free-Float 78.35%
More Fundamentals * Assessed data
Dynamic Chart
1 day-5.26%
1 week-2.70%
Current month-2.70%
1 month+5.88%
3 months-14.29%
6 months-28.00%
Current year-14.29%
More quotes
1 week
0.18
Extreme 0.18
0.19
1 month
0.17
Extreme 0.17
0.25
Current year
0.17
Extreme 0.17
0.25
1 year
0.15
Extreme 0.15
0.26
3 years
0.15
Extreme 0.15
0.97
5 years
0.15
Extreme 0.15
2.01
10 years
0.15
Extreme 0.15
2.35
More quotes
Managers TitleAgeSince
Chief Executive Officer - 22-04-17
Director of Finance/CFO 59 Feb. 13
Chief Tech/Sci/R&D Officer - 22-08-31
Members of the board TitleAgeSince
Director/Board Member - 22-04-17
Chief Executive Officer - 22-04-17
Director/Board Member - 22-12-07
More insiders
Date Price Change Volume
24-03-18 0.18 -5.26% 1,000
24-03-15 0.19 +2.70% 500
24-03-13 0.185 -2.63% 3,000
24-03-12 0.19 +2.70% 21,120

Delayed Quote Toronto S.E., March 18, 2024 at 09:30 am EDT

More quotes
Helix BioPharma Corp. is a Canada-based a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47. DOS47 is an oncology platform technology that offers a potentially approach to the debilitation and destruction of cancer cells. DOS47 is designed to stimulate an increase in the Potential of Hydrogen (pH) of the microenvironment surrounding the cancerous cells, effectively reversing the acidic extra cellular conditions that are believed to act to defend the tumor. L-DOS47 is an antibody protein conjugate where the urease component enzymatically converts naturally occurring urea to ammonia. The L-DOS47 drug molecule includes a specialized camelid-derived single domain antibody and is under clinical study for the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. V-DOS47 targets the vascular endothelial growth factor two recept
More about the company

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Helix BioPharma Corp. - Toronto S.E.